AstraZeneca’s Tagrisso Chemo Combo Impresses But Not A Gamechanger
Reduces Risk Of Lung Cancer Progression By 38%
The detailed results from FLAURA2 have provided a boost for AstraZeneca's Tagrisso franchise, although the combination of the drug plus chemotherapy is unlikely to challenge the convenience that the company's biggest earner already offers for most patients.
